Abstract: Disclosed herein are methods for identifying the neuronal and neurodegenerative phenotypes affected by and identified in Alzheimer's Disease, characterized as Alzheimer's Disease subtypes, methods for identifying drugs effective for treating Alzheimer's Disease subtypes, and drugs useful in treating Alzheimer's Disease subtypes.

Abstract: The present invention provide a method for the prevention and treatment of a neurodegenerative disease including Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease, using a grape seed extract or one or more compounds derived therefrom. In particular, the present invention provides a method to treat a patient diagnosed with, or at the risk of developing, a neurodegenerative disease by administering a pharmaceutical composition comprising a grape seed extract or one or more compounds derived therefrom to the patient in a therapeutic amount to reduce the accumulation, aggregation or deposition of amyloid beta or its oligomers, and/or to reduce the misfolding, accumulation and/or aggregation of tau proteins or other proteins.

Abstract: The present invention provide a method for the prevention and treatment of a neurodegenerative disease including Alzheimer's Disease, Huntington's Disease, and Parkinson's Disease, using a grape seed extract or one or more compounds derived therefrom. In particular, the present invention provides a method to treat a patient diagnosed with, or at the risk of developing, a neurodegenerative disease by administering a pharmaceutical composition comprising a grape seed extract or one or more compounds derived therefrom to the patient in a therapeutic amount to reduce the accumulation, aggregation or deposition of amyloid beta or its oligomers, and/or to reduce the misfolding, accumulation and/or aggregation of tau proteins or other proteins.

Abstract: The ability to monitor the progression of human immunodeficiency virus (HIV) infection in patients is paramount to the study of HIV transmission, in predicting the onset and advancement of disease, and evaluating the clinical efficacy of therapeutics. Present methods available to the clinician for the study of HIV pathogenesis employ surrogate markers. Surrogate markers are biological indicators that tend to reflect, to varying extent, the gradual progression of the asymptomatic state to the development of acquired immune deficiency syndrome (AIDS). The most commonly used markers are CD4.sup.+ lymphocyte counts and HIV p24 antigen production. The use of markers to evaluate disease progression suffers from a number of limitations. No known marker consistently reflects disease progression in all patients and stages of disease. Moreover, an effective marker must rapidly reflect the changes associated with antiviral therapy.